Biocompatible hydrogel treatments for retinal detachment
First Claim
Patent Images
1. An in vivo gelling pre-formulation for the treatment of retinal detachment, comprising:
- (a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic amino group;
wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from
6 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.
92 Citations
15 Claims
-
1. An in vivo gelling pre-formulation for the treatment of retinal detachment, comprising:
(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic amino group;
wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from- View Dependent Claims (2, 3, 4, 5, 6, 12, 13)
-
7. A method of treating retinal detachment, comprising delivering an in vivo gelling pre-formulation to a site of a retinal tear in a human eye, the in vivo gelling pre-formulation comprising:
(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic amino group;
wherein the nucleophilic arms of the multi-ARM nucleophilic polyol monomers are selected from- View Dependent Claims (8, 9, 10, 11, 14, 15)
Specification